{"prompt": "['GALDERMA R&D', 'RD.06.SPR.11829: Protocol V02 04Jun2019', 'Page 7 of 88', '11.4', 'Contractual requirements', '68', '11.5', 'Data collection and archiving', '68', '11.5.1', 'Data collection', '68', '11.5.2', 'Source documentation', '69', '11.5.3', 'Archives', '69', '11.6', 'Insurance', '69', '12', 'LITERATURE REFERENCE LIST', '69', '13', 'APPENDICES', '72', '13.1', 'Subject Satisfaction Questionnaire', '72', '13.2', 'Study Drug Acceptability Questionnaire', '74', '13.3', 'Dermatology Life Quality Index (DLQITM)', '75', '13.4', \"Children's Dermatology Life Quality Index (C-DLQITM)\", '77', '13.5', 'QOL Questionnaire for Face and Trunk Acne (16 years of age and older)', '79', '13.6', 'EuroQoL 5-Dimension (EQ-5D-5L)', '81', '13.7', 'Fitzpatrick Skin Classification', '83', '13.8', 'Acne Harmonization Lesion Count', '84', 'CCI', '13.10', 'Atrophic Acne Scar Counts', '87', 'Protocol Signature Page', '88']['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 8 of 88', 'List of Tables', 'Table 1', 'Clinical trial schematic', '13', 'Table 2', 'Schedule of assessments', '14', 'Table 3', 'Exit Form reasons for discontinuation', '31', 'Table 4', 'Description and usage of the study drug', '32', 'Table 5', 'Suspected sensitization - reaction grading', '49', 'Table 6', 'Suspected sensitization - conclusion', '49']['GALDERMA R&D', 'RD.06.SPR.11829: Protocol V02 04Jun2019', 'Page 9 of 88', 'SYNOPSIS', 'Clinical Trial Title: A Multi-Center Study to Evaluate Subject Reported Outcomes with use of Trifarotene 50 g/g', 'Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris', 'Short Title: Subject Reported Outcomes with use of Trifarotene 50 g/g Cream in Subjects with Moderate Facial', 'and Truncal Acne Vulgaris', 'Lay Title: Studying the Effects of 50g/g Cream on Subjects who have Acne', 'Clinical Trial phase:', 'IIIb', 'Clinical Trial Population:', 'Subjects with moderate acne vulgaris with facial and truncal acne involvement', 'Clinical Trial objectives:', 'The purpose of this study is to evaluate subject reported outcomes with Trifarotene', 'cream.', 'Clinical Trial design:', 'Multi-center, open label, single arm study of Trifarotene cream applied once daily in', 'the evening for 24 weeks.', 'Total number of subjects', 'Approximately 50 subjects will be enrolled in order to obtain 40 subjects at', '(Planned):', 'completion.', 'Number of clinical trial', 'centers (Planned):', 'Region(s) / country(ies)', 'United States', 'involved (Planned):', 'Clinical trial duration:', 'Duration of subject', 'Clinical trial participation for each subject is approximately 24 weeks of study', 'participation:', 'treatment +3 days.', 'Note: Subjects, upon study completion/early termination, will return to standard of', 'care with their physician.', 'Key inclusion criteria', '1.', 'Male or female, 9 years of age and older, at the Screening visit.', '2.', 'The Subject has a facial acne', 'CCI', 'Key exclusion criteria', '1.', 'The subject has severe forms of acne (e.g., acne conglobata, acne', 'fulminans) or secondary acne form (e.g. ,chloracne, drug-induced acne, etc.).']\n\n###\n\n", "completion": "END"}